# TELA Bio, Inc.: financial statements, quarterly

TELA · Nasdaq · CIK 1561921 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/tela.md) · [Financials](/companies/tela/financials.md) · [Filings](/companies/tela/filings.md) · [Insiders](/companies/tela/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/tela/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [15.1](/filings/0001558370-24-015050.md) | [17.0 d](/filings/0001104659-26-034507.md) | [16.6](/filings/0001558370-25-006994.md) | [16.1](/filings/0001558370-25-011052.md) | [19.0](/filings/0001104659-25-112476.md) | [17.6 d](/filings/0001104659-26-034507.md) | [18.5](/filings/0001104659-26-060234.md) | [20.2](/filings/0001104659-26-094039.md) | [20.7](/filings/0001104659-25-112476.md) | [20.9 d](/filings/0001104659-26-034507.md) | [19.1](/filings/0001104659-26-060234.md) | [19.3](/filings/0001104659-26-094039.md) |
| Gross profit | $m | [10.4](/filings/0001558370-24-015050.md) | [11.6 d](/filings/0001104659-26-034507.md) | [11.3](/filings/0001558370-25-006994.md) | [11.1](/filings/0001558370-25-011052.md) | [12.9](/filings/0001104659-25-112476.md) | [11.2 d](/filings/0001104659-26-034507.md) | [12.5](/filings/0001104659-26-060234.md) | [14.1](/filings/0001104659-26-094039.md) | [14.0](/filings/0001104659-25-112476.md) | [13.8 d](/filings/0001104659-26-034507.md) | [12.5](/filings/0001104659-26-060234.md) | [13.9](/filings/0001104659-26-094039.md) |
| Research and development | $m | [2.4](/filings/0001558370-24-015050.md) | [2.7 d](/filings/0001104659-26-034507.md) | [2.4](/filings/0001558370-25-006994.md) | [2.3](/filings/0001558370-25-011052.md) | [2.1](/filings/0001104659-25-112476.md) | [2.0 d](/filings/0001104659-26-034507.md) | [2.5](/filings/0001104659-26-060234.md) | [2.2](/filings/0001104659-26-094039.md) | [2.3](/filings/0001104659-25-112476.md) | [2.1 d](/filings/0001104659-26-034507.md) | [2.3](/filings/0001104659-26-060234.md) | [2.7](/filings/0001104659-26-094039.md) |
| Operating income | $m | [(10.2)](/filings/0001558370-24-015050.md) | [(12.3) d](/filings/0001104659-26-034507.md) | [(4.8)](/filings/0001558370-25-006994.md) | [(11.6)](/filings/0001558370-25-011052.md) | [(9.4)](/filings/0001104659-25-112476.md) | [(8.4) d](/filings/0001104659-26-034507.md) | [(10.5)](/filings/0001104659-26-060234.md) | [(9.1)](/filings/0001104659-26-094039.md) | [(7.6)](/filings/0001104659-25-112476.md) | [(6.6) d](/filings/0001104659-26-034507.md) | [(10.5)](/filings/0001104659-26-060234.md) | [(9.3)](/filings/0001104659-26-094039.md) |
| Interest expense | $m | [1.3](/filings/0001558370-23-018822.md) | [1.3 d](/filings/0001558370-24-003782.md) | [1.3](/filings/0001558370-24-007784.md) | [1.3](/filings/0001558370-25-011052.md) | [1.3](/filings/0001104659-25-112476.md) | [1.3 d](/filings/0001104659-26-034507.md) | [1.2](/filings/0001104659-26-060234.md) | [1.2](/filings/0001104659-26-094039.md) | [1.2](/filings/0001104659-25-112476.md) | [1.6 d](/filings/0001104659-26-034507.md) | [2.1](/filings/0001104659-26-060234.md) | [2.1](/filings/0001104659-26-094039.md) |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.1](/filings/0001104659-26-060234.md) | [0.0](/filings/0001104659-26-094039.md) | [0.0 d](/filings/0001104659-25-112476.md) | [0.1 d](/filings/0001104659-26-034507.md) | [0.1](/filings/0001104659-26-060234.md) | [0.1](/filings/0001104659-26-094039.md) |
| Net income | $m | [(11.0)](/filings/0001558370-24-015050.md) | [(12.9) d](/filings/0001104659-26-034507.md) | [(5.7)](/filings/0001558370-25-006994.md) | [(12.6)](/filings/0001558370-25-011052.md) | [(10.4)](/filings/0001104659-25-112476.md) | [(9.2) d](/filings/0001104659-26-034507.md) | [(11.3)](/filings/0001104659-26-060234.md) | [(9.9)](/filings/0001104659-26-094039.md) | [(8.6)](/filings/0001104659-25-112476.md) | [(9.0) d](/filings/0001104659-26-034507.md) | [(12.3)](/filings/0001104659-26-060234.md) | [(11.3)](/filings/0001104659-26-094039.md) |
| Diluted EPS | $ per share | [(0.45)](/filings/0001558370-24-015050.md) | not reported | [(0.23)](/filings/0001558370-25-006994.md) | [(0.51)](/filings/0001558370-25-011052.md) | [(0.42)](/filings/0001104659-25-112476.md) | not reported | [(0.25)](/filings/0001104659-26-060234.md) | [(0.22)](/filings/0001104659-26-094039.md) | [(0.19)](/filings/0001104659-25-112476.md) | not reported | [(0.21)](/filings/0001104659-26-060234.md) | [(0.20)](/filings/0001104659-26-094039.md) |
| Basic EPS | $ per share | [(0.45)](/filings/0001558370-24-015050.md) | not reported | [(0.23)](/filings/0001558370-25-006994.md) | [(0.51)](/filings/0001558370-25-011052.md) | [(0.42)](/filings/0001104659-25-112476.md) | not reported | [(0.25)](/filings/0001104659-26-060234.md) | [(0.22)](/filings/0001104659-26-094039.md) | [(0.19)](/filings/0001104659-25-112476.md) | not reported | [(0.21)](/filings/0001104659-26-060234.md) | [(0.20)](/filings/0001104659-26-094039.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [58.2](/filings/0001558370-23-018822.md) | [46.7](/filings/0001558370-25-003460.md) | [37.1](/filings/0001558370-25-006994.md) | [26.5](/filings/0001558370-25-011052.md) | [17.3](/filings/0001104659-25-112476.md) | [52.7](/filings/0001104659-26-034507.md) | [42.8](/filings/0001104659-26-060234.md) | [35.0](/filings/0001104659-26-094039.md) | [29.7](/filings/0001104659-25-112476.md) | [50.8](/filings/0001104659-26-094039.md) | [39.5](/filings/0001104659-26-060234.md) | [30.4](/filings/0001104659-26-094039.md) |
| Current assets | $m | [82.3](/filings/0001558370-23-018822.md) | [71.7](/filings/0001558370-25-003460.md) | [62.6](/filings/0001558370-24-007784.md) | [51.1](/filings/0001558370-24-012060.md) | [44.1](/filings/0001558370-24-015050.md) | [78.1](/filings/0001104659-26-034507.md) | [69.7](/filings/0001558370-25-006994.md) | [60.7](/filings/0001558370-25-011052.md) | [56.0](/filings/0001104659-25-112476.md) | [75.6](/filings/0001104659-26-094039.md) | [64.3](/filings/0001104659-26-060234.md) | [54.5](/filings/0001104659-26-094039.md) |
| Total assets | $m | [87.3](/filings/0001558370-23-018822.md) | [78.0](/filings/0001558370-25-003460.md) | [71.8](/filings/0001558370-24-007784.md) | [60.2](/filings/0001558370-24-012060.md) | [53.0](/filings/0001558370-24-015050.md) | [86.6](/filings/0001104659-26-034507.md) | [77.3](/filings/0001558370-25-006994.md) | [67.5](/filings/0001558370-25-011052.md) | [61.6](/filings/0001104659-25-112476.md) | [81.4](/filings/0001104659-26-094039.md) | [69.9](/filings/0001104659-26-060234.md) | [59.7](/filings/0001104659-26-094039.md) |
| Current liabilities | $m | [15.3](/filings/0001558370-23-018822.md) | [17.0](/filings/0001558370-25-003460.md) | [15.2](/filings/0001558370-24-007784.md) | [15.0](/filings/0001558370-24-012060.md) | [16.9](/filings/0001558370-24-015050.md) | [15.6](/filings/0001104659-26-034507.md) | [16.5](/filings/0001558370-25-006994.md) | [19.1](/filings/0001558370-25-011052.md) | [17.0](/filings/0001104659-25-112476.md) | [18.0](/filings/0001104659-26-094039.md) | [17.8](/filings/0001104659-26-060234.md) | [18.2](/filings/0001104659-26-094039.md) |
| Total liabilities | $m | [56.8](/filings/0001558370-23-018822.md) | [59.2](/filings/0001558370-25-003460.md) | [57.5](/filings/0001558370-24-007784.md) | [57.3](/filings/0001558370-24-012060.md) | [59.3](/filings/0001558370-24-015050.md) | [58.1](/filings/0001104659-26-034507.md) | [59.1](/filings/0001558370-25-006994.md) | [58.4](/filings/0001558370-25-011052.md) | [60.0](/filings/0001104659-25-112476.md) | [75.1](/filings/0001104659-26-094039.md) | [75.1](/filings/0001104659-26-060234.md) | [75.6](/filings/0001104659-26-094039.md) |
| Long-term debt | $m | [40.4](/filings/0001558370-23-018822.md) | [40.5](/filings/0001558370-25-003460.md) | [40.7](/filings/0001558370-24-007784.md) | [40.8](/filings/0001558370-24-012060.md) | [41.0](/filings/0001558370-24-015050.md) | [41.1](/filings/0001104659-26-034507.md) | [41.3](/filings/0001558370-25-006994.md) | [38.1](/filings/0001558370-25-011052.md) | [41.5](/filings/0001104659-25-112476.md) | [55.7](/filings/0001104659-26-094039.md) | [55.9](/filings/0001104659-26-060234.md) | [56.1](/filings/0001104659-26-094039.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [3.3](/filings/0001558370-25-011052.md) | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [30.6](/filings/0001558370-24-015050.md) | [18.9](/filings/0001104659-26-034507.md) | [14.4](/filings/0001558370-25-011052.md) | [2.9](/filings/0001104659-25-112476.md) | [(6.3)](/filings/0001104659-25-112476.md) | [28.5](/filings/0001104659-26-094039.md) | [18.1](/filings/0001104659-26-094039.md) | [9.2](/filings/0001104659-26-094039.md) | [1.6](/filings/0001104659-25-112476.md) | [6.3](/filings/0001104659-26-094039.md) | [(5.2)](/filings/0001104659-26-094039.md) | [(15.9)](/filings/0001104659-26-094039.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(7.0) d](/filings/0001558370-24-015050.md) | [(11.1) d](/filings/0001104659-26-034507.md) | [(14.4)](/filings/0001558370-25-006994.md) | [(10.7) d](/filings/0001558370-25-011052.md) | [(9.0) d](/filings/0001104659-25-112476.md) | [(7.5) d](/filings/0001104659-26-034507.md) | [(9.7)](/filings/0001104659-26-060234.md) | [(7.9) d](/filings/0001104659-26-094039.md) | [(5.7) d](/filings/0001104659-25-112476.md) | [(4.9) d](/filings/0001104659-26-034507.md) | [(11.2)](/filings/0001104659-26-060234.md) | [(9.4) d](/filings/0001104659-26-094039.md) |
| Capital expenditure | $m | [0.1 d](/filings/0001558370-24-015050.md) | [0.2 d](/filings/0001104659-26-034507.md) | [0.3](/filings/0001558370-25-006994.md) | [0.3 d](/filings/0001558370-25-011052.md) | [0.1 d](/filings/0001104659-25-112476.md) | [0.3 d](/filings/0001104659-26-034507.md) | [0.0](/filings/0001104659-26-060234.md) | [0.1 d](/filings/0001104659-26-094039.md) | [0.2 d](/filings/0001104659-25-112476.md) | [0.1 d](/filings/0001104659-26-034507.md) | [0.1](/filings/0001104659-26-060234.md) | [0.1 d](/filings/0001104659-26-094039.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [16.8](/filings/0001558370-23-018822.md) | [19.2](/filings/0001558370-24-007784.md) | [23.2](/filings/0001558370-24-012060.md) | [24.5](/filings/0001558370-24-015050.md) | [24.6](/filings/0001558370-25-006994.md) | [24.7](/filings/0001558370-25-011052.md) | [24.7](/filings/0001104659-25-112476.md) | [45.3](/filings/0001104659-26-060234.md) | [45.4](/filings/0001104659-26-094039.md) | [45.4](/filings/0001104659-25-112476.md) | [57.3](/filings/0001104659-26-060234.md) | [57.4](/filings/0001104659-26-094039.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 44,894,757 at 2026-08-05, from the cover of the [10-Q filed 2026-08-11](/filings/0001104659-26-094039.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:43 ET. No prices; not investment advice.